Drug intelligence / Profile preview

alprazolam

Development stage
Approved
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

Alprazolam is a fast-acting, high-potency triazolobenzodiazepine used primarily for the treatment of anxiety disorders and panic disorder, including anxiety associated with depression. It acts as a central nervous system depressant by binding to the benzodiazepine site on the GABA A receptor complex in the brain, enhancing the inhibitory effects of gamma aminobutyric acid (GABA). This results in decreased abnormal excitement and produces anxiolytic, anticonvulsant, muscle relaxant, hypnotic, and amnesic effects. Alprazolam is metabolized mainly by CYP3A enzymes and should not be used with strong CYP3A inhibitors. It was first approved by the FDA in 1981 and is available only by prescription[1][2][4][5][7].

Brand names
XanaxXanax XRNiravamAlprazolam IntensolGabazolamine-0.5Gabazolamine0.5Gabazolamine 0.5Alti-ALPRAZolam
Other names
Farmapram
02

Targets

BZD site (GABA-A receptor benzodiazepine site)

Beyond the preview

Go deeper on alprazolam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alprazolam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call